Showing 8561-8570 of 9751 results for "".
- Hair Restoration Doctors Name Best Celebrity Hair, Meeting Convenes October 23https://practicaldermatology.com/news/20131010-hair_restoration_doctors_name_best_celebrity_hair_meeting_convenes_october_23/2459438/Singer/songwriter John Mayer and “Modern Family” star Sofia Vergara are the male and female celebrities with the most sought-after hair, according to results of the International Society of Hair Restoration Surgery (ISHRS) member survey released rec
- ALPHAEON Acquires Exclusive Worldwide Licensing Rights To TouchMDhttps://practicaldermatology.com/news/20131010-alphaeon_acquires_exclusive_worldwide_licensing_rights_to_touchmd/2459439/ALPHAEON Corp., a leader in lifestyle healthcare and wholly-owned subsidiary of Strathspey Crown Holdings LLC, announced today that it has acquired worldwide licensing rights to TouchMD, for an undisclosed amount. TouchMD is an interactive software platform that helps speciality physicians educate p
- Cimzia FDA Approved to Treat Active Psoriatic Arthritis in Adultshttps://practicaldermatology.com/news/20131001-cimzia_receives_fda_approval_to_treat_adults_with_active_psoriatic_arthritis/2459446/The FDA recently approved UCB's Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis (PsA). The FDA approval of Cimzia for active PsA is based on data from the RAPID-PsA study, an ongoing, Phase III, multicenter, randomized,
- KYTHERA Announces Positive ATX-101 Top Line Phase III Trial Resultshttps://practicaldermatology.com/news/20130925-kythera_announces_positive_atx-101_top_line_phase_iii_trial_results/2459452/KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced that its ATX-101 REFINE-1 and REFINE-2 Phase III trials met all primary and secondary endpoints. These two pivotal Phase III trials were conducted in the U.S. and Canada to compare the efficacy and safety of a 2 mg/cm2 dose of ATX-101 v
- Precision Dermatology Names New CEOhttps://practicaldermatology.com/news/20130924-precision_dermatology_names_new_ceo/2459455/Robert J. Moccia has been appointed to the position of Chief Executive Officer at Precision Dermatology Inc. Mr. Moccia has led the introduction of a number of new strategies for growth since joining the company in January of this year. Mr. Moccia has 30 years of experience in dermatology, having mo
- ResurFX for M22 Platform from Lumenis Receives FDA Clearancehttps://practicaldermatology.com/news/20130917-resurfx_for_m22_platform_from_lumenis_receives_fda_clearance/2459459/The FDA recently granted 510(k) clearance for ResurFX, a new fractional non-ablative laser module from Lumenis. ResurFX is the latest application module for the company's M22 platform, expanding its capabilities to perform true fractional non-ablative skin resurfacing.
- GSK Receives FDA Priority Review for Dabrafenib/Trametinib Combination in Metastatic Melanomahttps://practicaldermatology.com/news/20130916-gsk_receives_priority_review_from_fda_for_dabrafenibtrametinib_combination_in_metastatic_melanoma/2459460/The FDA has granted priority review designation to GlaxoSmithKline's supplemental New Drug Applications (sNDAs) for combined use of Tafinlar (dabrafenib) and Mekinist (trametinib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 E or
- Exuviance Launches Age Less Everyday Daily Moisturizerhttps://practicaldermatology.com/news/20130912-exuviance_launches_age_less_everydaydaily_moisturizer/2459462/NeoStrata Company, Inc., recently introduced Exuviance Age Less Everyday, a daily moisturizer formulated to correct the signs of aging for skin that is dry, sensitive, or easily impacted by everyday stressors. Exuviance Age Less Everyday is formulated w
- FDA Approves Botox Cosmetic to Treat Crow's Feet Lines in Adultshttps://practicaldermatology.com/news/20130912-fda_approves_botox_cosmetic_to_treat_crows_feet_lines_in_adults/2459463/The FDA recently approved Botox Cosmetic (onabotulinumtoxinA) for an additional indication to temporarily treat moderate to severe lateral canthal lines. Allergan's
- Roche's Erivedge OK'd in Canadahttps://practicaldermatology.com/news/20130827-roches_erivedge_okd_in_canada/2459474/Erivedge (vismodegib) was recently approved in Canada for the treatment of adult patients with histologically confirmed metastatic basal cell carcinoma or locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy.